Cargando…

Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries

The use of mesenchymal stem cells (MSCs) for the treatment of equine tendon disease is widely investigated because of their regenerative and immunomodulatory potential. However, questions have been raised concerning the immunogenic properties of allogeneic MSCs. Therefore, two studies were conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Depuydt, Eva, Broeckx, Sarah Y., Chiers, Koen, Patruno, Marco, Da Dalt, Laura, Duchateau, Luc, Saunders, Jimmy, Pille, Frederik, Martens, Ann, Van Hecke, Lore, Spaas, Jan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907452/
https://www.ncbi.nlm.nih.gov/pubmed/35281431
http://dx.doi.org/10.3389/fvets.2021.789293
_version_ 1784665646107197440
author Depuydt, Eva
Broeckx, Sarah Y.
Chiers, Koen
Patruno, Marco
Da Dalt, Laura
Duchateau, Luc
Saunders, Jimmy
Pille, Frederik
Martens, Ann
Van Hecke, Lore
Spaas, Jan H.
author_facet Depuydt, Eva
Broeckx, Sarah Y.
Chiers, Koen
Patruno, Marco
Da Dalt, Laura
Duchateau, Luc
Saunders, Jimmy
Pille, Frederik
Martens, Ann
Van Hecke, Lore
Spaas, Jan H.
author_sort Depuydt, Eva
collection PubMed
description The use of mesenchymal stem cells (MSCs) for the treatment of equine tendon disease is widely investigated because of their regenerative and immunomodulatory potential. However, questions have been raised concerning the immunogenic properties of allogeneic MSCs. Therefore, two studies were conducted to assess the safety of equine allogeneic peripheral blood-derived tenogenic primed MSCs (tpMSCs). The objective was to evaluate if a single and repeated tpMSC administration induced a cellular and humoral immune response in horses suffering from tendon injuries. Horses enrolled in the first study (n = 8) had a surgically induced superficial digital flexor tendon core lesion and were treated intralesionally with tpMSCs. Before and after treatment the cellular immunogenicity was assessed by modified mixed lymphocyte reactions. The humoral immune response was investigated using a crossmatch assay. Presence of anti-bovine serum albumin (BSA) antibodies was detected via ELISA. Horses enrolled in the second study (n = 6) suffered from a naturally occurring tendon injury and were treated twice with tpMSCs. Blood was collected after the second treatment for the same immunological assays. No cellular immune response was found in any of the horses. One out of eight horses in the first study and none of the horses in the second study had anti-tpMSC antibodies. This particular horse had an equine sarcoid and further investigation revealed presence of antibodies against sarcoid cells and epithelial-like stem cells before treatment, which increased after treatment. Additionally, formation of antibodies against BSA was observed. These findings might indicate a non-specific immune response generated after treatment. Serum from the other horses revealed no such antibody formation. These two studies showed that the administration of tpMSCs did not induce a cellular or humoral immune response following an intralesional single or repeated (two consecutive) allogeneic tpMSC treatment in horses with tendon injury, except for one horse. Therefore, a larger field study should confirm these findings and support the safe use of tpMSCs as a therapeutic for horses suffering from tendon injuries.
format Online
Article
Text
id pubmed-8907452
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89074522022-03-11 Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries Depuydt, Eva Broeckx, Sarah Y. Chiers, Koen Patruno, Marco Da Dalt, Laura Duchateau, Luc Saunders, Jimmy Pille, Frederik Martens, Ann Van Hecke, Lore Spaas, Jan H. Front Vet Sci Veterinary Science The use of mesenchymal stem cells (MSCs) for the treatment of equine tendon disease is widely investigated because of their regenerative and immunomodulatory potential. However, questions have been raised concerning the immunogenic properties of allogeneic MSCs. Therefore, two studies were conducted to assess the safety of equine allogeneic peripheral blood-derived tenogenic primed MSCs (tpMSCs). The objective was to evaluate if a single and repeated tpMSC administration induced a cellular and humoral immune response in horses suffering from tendon injuries. Horses enrolled in the first study (n = 8) had a surgically induced superficial digital flexor tendon core lesion and were treated intralesionally with tpMSCs. Before and after treatment the cellular immunogenicity was assessed by modified mixed lymphocyte reactions. The humoral immune response was investigated using a crossmatch assay. Presence of anti-bovine serum albumin (BSA) antibodies was detected via ELISA. Horses enrolled in the second study (n = 6) suffered from a naturally occurring tendon injury and were treated twice with tpMSCs. Blood was collected after the second treatment for the same immunological assays. No cellular immune response was found in any of the horses. One out of eight horses in the first study and none of the horses in the second study had anti-tpMSC antibodies. This particular horse had an equine sarcoid and further investigation revealed presence of antibodies against sarcoid cells and epithelial-like stem cells before treatment, which increased after treatment. Additionally, formation of antibodies against BSA was observed. These findings might indicate a non-specific immune response generated after treatment. Serum from the other horses revealed no such antibody formation. These two studies showed that the administration of tpMSCs did not induce a cellular or humoral immune response following an intralesional single or repeated (two consecutive) allogeneic tpMSC treatment in horses with tendon injury, except for one horse. Therefore, a larger field study should confirm these findings and support the safe use of tpMSCs as a therapeutic for horses suffering from tendon injuries. Frontiers Media S.A. 2022-02-24 /pmc/articles/PMC8907452/ /pubmed/35281431 http://dx.doi.org/10.3389/fvets.2021.789293 Text en Copyright © 2022 Depuydt, Broeckx, Chiers, Patruno, Da Dalt, Duchateau, Saunders, Pille, Martens, Van Hecke and Spaas. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Depuydt, Eva
Broeckx, Sarah Y.
Chiers, Koen
Patruno, Marco
Da Dalt, Laura
Duchateau, Luc
Saunders, Jimmy
Pille, Frederik
Martens, Ann
Van Hecke, Lore
Spaas, Jan H.
Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries
title Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries
title_full Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries
title_fullStr Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries
title_full_unstemmed Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries
title_short Cellular and Humoral Immunogenicity Investigation of Single and Repeated Allogeneic Tenogenic Primed Mesenchymal Stem Cell Treatments in Horses Suffering From Tendon Injuries
title_sort cellular and humoral immunogenicity investigation of single and repeated allogeneic tenogenic primed mesenchymal stem cell treatments in horses suffering from tendon injuries
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907452/
https://www.ncbi.nlm.nih.gov/pubmed/35281431
http://dx.doi.org/10.3389/fvets.2021.789293
work_keys_str_mv AT depuydteva cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT broeckxsarahy cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT chierskoen cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT patrunomarco cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT dadaltlaura cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT duchateauluc cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT saundersjimmy cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT pillefrederik cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT martensann cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT vanheckelore cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries
AT spaasjanh cellularandhumoralimmunogenicityinvestigationofsingleandrepeatedallogeneictenogenicprimedmesenchymalstemcelltreatmentsinhorsessufferingfromtendoninjuries